This Could Have Been The First Poop Pill To Hit The Market, But It Failed Clinical Trials
[...] “I think it is a big deal,” said Rachel Sachs, a professor of health and law at Washington University in St. Louis, who has researched how microbial therapies could be regulated by agencies. “I would say this is good news for Rebiotix — to the extent it doesn’t have the same problem.” [...]
Read the full article here.